Skip to main content

Table 3 Risk factors of treatment discontinuation of paliperidone palmitate or risperidone microsphere by univariate and multivariate Cox regression analysis

From: Assessment of risk factors of treatment discontinuation among patients on paliperidone palmitate and risperidone microspheres in France, Germany and Belgium

 

Univariate

Multivariate (including Belgian data)

Multivariate (excluding Belgian data)

Variable

Reference

Class

HR

P value^

HR

P value^

HR

P value^

Gender

Men

Women

1.07

 < .0001

1.05

0.001

1.05

0.002

Agea

18–30 years

31–50 years

0.96

0.051

-

-

0.95

0.006

  

 > 50 years

0.97

0.20

-

-

0.91

 < .0001

Type of treatment

Paliperidone palmitate

Risperidone microsphere

2.08

 < .0001

1.96

 < .0001

1.97

 < .0001

Previous treatment

Other LAT

Oral AP

1.39

 < .0001

1.22

 < .0001

1.22

 < .0001

  

No AP

1.36

 < .0001

1.22

 < .0001

1.21

 < .0001

Dosage per 30 daysb

 < 75 mg

75–125 mg

0.94

0.003

0.98

0.36

0.98

0.27

  

 > 125 mg

0.81

 < .0001

0.95

0.018

0.95

0.037

Combination therapy

Monotherapy

Combination therapy

1.05

0.003

1.05

0.001

1.06

0.001

Specialty of the prescribers

Psychiatrist only

GP only

1.68

 < .0001

1.37

 < .0001

1.36

 < .0001

  

Psychiatrist + GP

0.81

 < .0001

0.76

 < .0001

0.78

 < .0001

  

Other

0.82

 < .0001

0.82

 < .0001

0.81

 < .0001

Other treatmentsc

None

1 molecule

1.04

0.11

1.02

0.46

1.01

0.63

  

2 molecules

1.03

0.23

0.98

0.47

0.98

0.53

  

 > 2 molecules

1.05

0.008

0.99

0.77

1.00

0.85

  1. ^P-values in bold are those with p-values < 0.05
  2. aAge was not available in the Belgian database. The Belgian data was not included in the univariate analysis using age as a covariate but was used all remaining univariate analyses
  3. bThe recommended monthly dose of the three study drugs was similar per SmPC (50 mg per 30 days), i.e. risperidone microspheres for 25 mg every two weeks, PP1M for 50 mg per month and PP3M for 175 mg per three months
  4. cBased on the number of distinct molecules other than antipsychotics purchased, patients were classified into four groups: patients who purchased 0, 1, 2 and more than 2 distinct other molecules during the first three months after